MiR‐34c was identified as upregulated in both AD and T2DM in the present study, and it was shown to downregulate MAP2K1, among other targets, to enhance proinsulin synthesis during the formation of insulin‐producing cells (IPCs). Here, MAP2K1 is linked to Alzheimer disease.